Research brief · 2026-09-09
What Does MOTS-c Actually Do? What the Research Shows
MOTS-c is a small peptide the body already makes. It is encoded by a short reading frame inside mitochondrial DNA, the genetic material of the cell's energy-producing organelles, rather than being cut from an existing protein. It has never been approved as a medicine, and no verified human trial has ever administered it.
Almost everything known about giving MOTS-c as a treatment comes from mouse studies. In diet-induced obese mice and transgenic models, administered MOTS-c has been reported to improve insulin sensitivity, activate the energy-sensing pathway AMPK, improve skeletal muscle mitochondrial function and reduce oxidative stress markers. A 2022 review by Yoon and colleagues in Diabetes and Metabolism Journal summarizes that work, and a 2026 study by Gudiksen and colleagues in Free Radical Biology and Medicine found improved muscle mitochondrial efficiency in transgenic mice.
The human research is a different kind of study. Rather than giving people MOTS-c, researchers measure the MOTS-c their bodies already produce. Von Walden and colleagues, in the Journal of Applied Physiology in 2021, found circulating MOTS-c rose after endurance exercise. Kutuk and colleagues, in Scientific Reports in 2026, found lower levels in women with polycystic ovary syndrome than in matched controls. These are correlations with a natural peptide, not effects of a drug.
One record on ClinicalTrials.gov does name MOTS-c as an investigational treatment for prediabetes. But its sponsor, single site and investigator are identical to at least three other registry records already identified as fabricated template listings, with a near-identical completion date. It should not be treated as evidence that a genuine trial is underway.
The limit is total. No human has received MOTS-c in a verified trial, so whether any of the mouse effects occur in people, and what happens with repeated use, is unknown. MOTS-c is not approved for human use, and the evidence is animal only.
Sources
- Yoon TK et al., Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c), review of animal administration studies
- Diabetes & Metabolism Journal 2022
- von Walden F et al., Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans (observational)
- Journal of Applied Physiology 2021
- Kutuk MS et al., Reduced serum and skeletal muscle MOTS-c levels in women with polycystic ovary syndrome (observational)
- Scientific Reports 2026
- Gudiksen A et al., MOTS-c improves intrinsic muscle mitochondrial bioenergetic health in a PGC-1a/AMPK-dependent manner (transgenic mice)
- Free Radical Biology & Medicine 2026
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.